Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2021 Financial Results
Fate Therapeutics (NASDAQ: FATE) announced a conference call for November 4, 2021, at 5:00 p.m. ET to discuss its third quarter 2021 financial results and corporate updates. Shareholders can join the call by dialing (877) 303-6235 domestically or (631) 291-4837 internationally, using conference ID 9459084. The live audio webcast will be available under the Events section of the company's website. Fate Therapeutics focuses on developing first-in-class cellular immunotherapies for cancer, leveraging its proprietary induced pluripotent stem cell technology.
- Fate Therapeutics is committed to developing first-in-class cellular immunotherapies for cancer.
- The company has a robust pipeline of immuno-oncology products.
- None.
SAN DIEGO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that the Company will host a conference call and live audio webcast on Thursday, November 4, 2021 at 5:00 p.m. ET to report its third quarter 2021 financial results and provide a corporate update.
In order to participate in the conference call, please dial (877) 303-6235 (domestic) or (631) 291-4837 (international) and refer to conference ID 9459084. The live webcast can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.fatetherapeutics.com. The archived webcast will be available on the Company's website beginning approximately two hours after the event.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology pipeline includes off-the-shelf, iPSC-derived natural killer (NK) cell and T-cell product candidates, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens using chimeric antigen receptors (CARs). Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina.tartaglia@sternir.com
FAQ
When will Fate Therapeutics announce its Q3 2021 financial results?
How can I participate in the Fate Therapeutics conference call?
What is Fate Therapeutics known for?
Where can I find the archived webcast of Fate Therapeutics' conference call?
